GlassScriptPhysician profile
Michelle Sewon Min
NPI 1194176354
$44,751.74
in general payments reported to CMS, 2019-2025
20 companies · $31K in 2025
The $31K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,231 · 2020: $238 · 2021: $99.00 · 2022: $2,787 · 2023: $7,837 · 2024: $1,089 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Travel and Lodging: $5,256 · Food and Beverage: $2,850 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,190.00 |
| Travel and Lodging | $5,256.39 |
| Food and Beverage | $2,850.15 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27,644.72 | 2023-2025 | Sotyktu |
| Ucb, INC. | $10,972.57 | 2024-2025 | Bimzelx |
| Horizon Therapeutics Plc | $2,682.05 | 2022 | |
| Janssen Biotech, INC. | $815.44 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $813.96 | 2019-2025 | |
| Abbvie INC. | $282.69 | 2019-2023 | |
| Leo Pharma INC. | $276.33 | 2022-2025 | Adbry, Anzupgo |
| Janssen Scientific Affairs, LLC | $234.41 | 2019-2025 | Tremfya |
| Pfizer INC. | $232.19 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $138.68 | 2025 | |
| Astrazeneca Uk Limited | $129.00 | 2025 | Saphnelo |
| Lilly USA, LLC | $100.00 | 2019 | |
| Allergan, INC. | $97.33 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $92.36 | 2024 | Dupixent |
| Galderma Laboratories, L.P. | $89.23 | 2020-2025 | Nemluvio |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $52.89 | 2020 | |
| Amgen INC. | $52.89 | 2020 | |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Min listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.